Alerts will be sent to your verified email
Verify EmailLAURUSLABS
Laurus Labs
|
PI Industries
|
Aurobindo Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
83.0 . | n/a | 291.0 . |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in Europe
|
18.0 | n/a | n/a |
Number of ANDA's Approved in Europe
|
14.0 | n/a | n/a |
Number of ANDA's Filed in USA
|
40.0 . | n/a | 830.0 . |
Number of ANDA's Approved By USFDA
|
32.0 . | n/a | 685.0 . |
Number of ANDA's Approved by Canada
|
15.0 | n/a | n/a |
Number of ANDA's Filed in Canada
|
22.0 | n/a | n/a |
R&D as a % of Total Sales
|
4.8 % | n/a | 5.2 % |
Financials
|
|||
5 yr Average ROE
|
20.05 % | 16.01 % | 15.24 % |
5yr average Equity Multiplier
|
2.06 | 1.59 | 1.59 |
5yr Average Asset Turnover Ratio
|
0.74 | 0.64 | 0.72 |
5yr Avg Net Profit Margin
|
12.47 % | 15.8 % | 13.0 % |
Price to Book
|
5.74 | 6.53 | 2.38 |
P/E
|
149.57 | 33.9 | 22.4 |
5yr Avg Cash Conversion Cycle
|
109.81 Days | 30.17 Days | -29.67 Days |
Inventory Days
|
110.32 Days | 71.45 Days | 60.22 Days |
Days Receivable
|
117.42 Days | 44.38 Days | 30.42 Days |
Days Payable
|
143.67 Days | 101.84 Days | 111.73 Days |
5yr Average Interest Coverage Ratio
|
9.19 | 48.31 | 43.11 |
5yr Avg ROCE
|
24.17 % | 18.47 % | 18.43 % |
5yr Avg Operating Profit Margin
|
24.88 % | 24.01 % | 20.43 % |
5 yr average Debt to Equity
|
0.56 | 0.06 | 0.27 |
5yr CAGR Net Profit
|
-9.19 % | 24.55 % | -4.01 % |
5yr Average Return on Assets
|
9.61 % | 10.13 % | 9.53 % |
Shareholdings
|
|||
Promoter Holding
|
27.19 % | 46.09 % | 51.83 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 20.86 % |
Change in Promoter Holding (3 Yrs)
|
-0.26 % | -0.65 % | -0.11 % |
Change in Mutual Fund Holding (3 Yrs)
|
4.63 % | 1.13 % | 8.99 % |
Laurus Labs
|
PI Industries
|
Aurobindo Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|